文献速递肿瘤 PET/CT核素与放射性配体治疗

早期滤泡性淋巴瘤FDG-PET分期后单纯放疗的结局

Outcome of patients with early-stage follicular lymphoma staged with 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET) and treated with radiotherapy alone.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-08-07

本研究纳入47例经PET分期并接受单纯根治性放疗的早期(I–II期)滤泡性淋巴瘤患者,评估PET分期对总生存和无进展生存的影响。PET分期I期较II期5年PFS显著更优(84%对60%,HR 4.66,95%CI 1.15–18.8,p=0.038),而CT分期I期与II期PFS无显著差异。7年OS为91%(95%CI 79–100)。作者认为FDG-PET应被视为考虑放疗的ESFL患者评估中的必要元素。

要点

  • PET分期I期较II期5年PFS显著更优(84%对60%,HR 4.66,95%CI 1.15–18.8,p=0.038)。
  • CT分期I期与II期PFS无显著差异(HR 1.30,95%CI 0.25–6.72,p=0.75)。
  • 全队列7年OS为91%(95%CI 79–100)。

核心结论

  • 作者认为FDG-PET应被视为考虑放疗的早期滤泡性淋巴瘤患者评估中的必要元素。

研究设计与样本

  • 回顾性分析2000年12月至2011年5月间接受根治性放疗的85例早期(I–II期)滤泡性淋巴瘤患者,排除13例无PET分期及25例接受额外全身治疗者,最终分析47例经PET分期并接受单纯根治性放疗(剂量>23Gy)的患者。

主要发现

  • 中位年龄57岁(范围24–83),女性占43%,PET分期I期占76.6%,中位最大淋巴结直径3cm,中位治疗前LDH为327.5(范围123–607,正常上限220),55.3%为膈下病变。
  • 所有患者接受30–36Gy分15–24次放疗,59.6%采用累及野放疗(IFRT)技术。
  • CT分期I期与II期PFS无显著差异(HR 1.30,95%CI 0.25–6.72,p=0.75),5年PFS分别为77%和78%。
  • PET分期I期较II期PFS显著更优(HR 4.66,95%CI 1.15–18.8,p=0.038),5年PFS分别为84%和60%。
  • 10例患者复发,其中7例首发失败部位为远处病变;全队列7年OS为91%(95%CI 79–100)。

临床怎么用

  • 作者认为FDG-PET应被视为考虑放疗的早期滤泡性淋巴瘤患者评估中的必要元素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE/OBJECTIVE(S): To evaluate the impact of positron emission tomography (PET) staging on overall survival (OS) and progression-free survival (PFS) in patients with early-stage (stages I and II) follicular lymphoma (ESFL) treated with radiation therapy alone. MATERIALS/METHODS: Eighty-five patients with ESFL treated with curative-intent radiation therapy (RT) between December 2000 and May 2011 were identified. Of those, 13 who had no PET staging and 25 who received additional systemic therapy were excluded from the analysis. Thus, we analyzed 47 patients with PET-staged ESFL treated with definitive radiation therapy alone (dose > 23Gy). Tumour features, pre-treatment computed tomography (CT) and PET stage, dose fractionation, and radiation therapy field extent were recorded. The Kaplan-Meier method was used to estimate the OS and PFS. Patterns of failure were assessed as cumulative incidences assuming competing risks. RESULTS: Median age was 57 years (range 24-83); 43% were females. Most were PET stage 1 (76.6%). Median maximum nodal diameter was 3 cm. Median pre-treatment lactate dehydrogenase (LDH) was 327.5 (range 123-607, upper normal limit = 220). Twenty-six patients (55.3%) had infra-diaphragmatic disease. All received 30-36Gy in 15-24 fractions, with 59.6% treated with involved-field radiation therapy (IFRT) techniques. There was no significant difference in PFS between CT stage I and stage II (HR 1.30 95% CI [0.25-6.72], p = 0.75) with a 5-year PFS of 77% and 78% respectively. However, stage I on PET staging had a significantly better PFS than stage II (HR 4.66 95% CI [1.15-18.8], p = 0.038), with 5-year PFS of 84% and 60% respectively. Ten patients had recurrent disease, with distant disease being the first site of failure in seven patients. Seven-year OS was 91% (95% CI 79-100) for the whole cohort. CONCLUSION: FDG-PET should be considered an essential element in the evaluation of patients with ESFL being considered for RT.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Ng SP, Khor R, Bressel M, et al. Outcome of patients with early-stage follicular lymphoma staged with 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET) and treated with radiotherapy alone. Eur J Nucl Med Mol Imaging. 2018. PMID: 30083824. doi:10.1007/s00259-018-4112-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。